Active — Not RecruitingNot Applicable

Primary Hormone-sensitive Breast Cancer: Need-driven Health Care Improvement by Patient-centred Digital Application

Germany400 participantsStarted 2022-01-01

Plain-language summary

The investigators designed a prospective, 2-armed, cluster-randomized multicenter clinical trial on the effect of a by a digital application triggered intervention on quality of life and therapy-adherence among breast cancer patients, compared to standard of care.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * primary, hormone-sensitive breast cancer * indication for adjuvant endocrine therapy (aromatase-inhibitor, tamoxifen, GnRH-analogue allone or in combination with tamoxifen/ aromatas inhibitor; combination of endocrine therapy with CDK 4/6-inhibitor/ antibody therapy/ radiotherapy) * start of endocrine therapy \<= 3 months ago * patients with public health ensurance * patients who are legally competent and able to understand and follow instructions of the study staff * present informed consent Exclusion Criteria: * no use of internet or digital applications * advanced, metastatic breast cancer * simultaneous serious disease * life expectancy \< 2 years

What they're measuring

Quality of Life (QOL)

Timeframe: 24 Months

Trial details

NCT IDNCT05503160

SponsorTechnical University of Munich

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12

View on ClinicalTrials.gov More New Healthcare Approach trials